|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1996-5-17
|
|
pubmed:abstractText |
Treatment of patients with metastatic renal cell carcinoma with high-dose interleukin-2 (IL-2) administered as continuous intravenous (CIV) infusion or as bolus injection results in response rates of 15% to 30%; however, toxicities with these regimens have been severe. A trial in which CIV IL-2 was administered at high doses during days 1 to 5 and at reduced doses during days 10 to 20 reported less toxicity without a decrease in response rates. We treated a series of patients with this regimen and our experience is presented.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0090-4295
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
194-7
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8607232-Adjuvants, Immunologic,
pubmed-meshheading:8607232-Adult,
pubmed-meshheading:8607232-Aged,
pubmed-meshheading:8607232-Carcinoma, Renal Cell,
pubmed-meshheading:8607232-Drug Therapy, Combination,
pubmed-meshheading:8607232-Female,
pubmed-meshheading:8607232-Humans,
pubmed-meshheading:8607232-Infusions, Intravenous,
pubmed-meshheading:8607232-Interleukin-2,
pubmed-meshheading:8607232-Kidney Neoplasms,
pubmed-meshheading:8607232-Male,
pubmed-meshheading:8607232-Middle Aged,
pubmed-meshheading:8607232-Pentoxifylline,
pubmed-meshheading:8607232-Remission Induction,
pubmed-meshheading:8607232-Time Factors
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience.
|
|
pubmed:affiliation |
University of Chicago, Illinois, USA.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
